Panacea Venture

Panacea Venture

投资管理

Building tomorrow's breakthroughs

关于我们

Panacea Venture is a life sciences venture capital firm with global vision and presence across three continents. The firm was founded in 2017 and is currently managing four funds investing in early-stage companies through public investments. Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale. The investment team has more than 100 years of combined investing experience and, along with venture partners and advisors, provides broad coverage across emerging and established biotech, diagnostic and medtech sectors. In addition, Panacea’s highly experienced team has a strong track record navigating portfolio companies to success.

网站
https://www.panaceaventure.com
所属行业
投资管理
规模
11-50 人
总部
Silicon Valley
类型
合营企业
创立
2017
领域
Investment Managment、Healthcare 、Biotechnology、Venture Capital和Lifesciences

地点

Panacea Venture员工

动态

  • Panacea Venture转发了

    查看Myrtelle的公司主页,图片

    984 位关注者

    Dayton Children’s Hospital, clinical site for Myrtelle’s Phase 1/2 Gene Therapy Trial for Canavan Disease, created the below video that features one of our treated patients. The reel highlights the love and perseverance of this beautiful family, while eloquently telling their story and the positive outcomes they are celebrating. May this inspire further work and treatments for diseases with unmet needs.

    查看Dayton Children's Hospital的公司主页,图片

    22,449 位关注者

    Juan and Natalia Lavato, from Argentina, had their world changed when their son, Ciro, was diagnosed with Canavan disease, a rare degenerative condition that damages nerve cells in the brain, affecting vision, speech and motor functions. After consulting ten specialists to confirm his diagnosis, they found what mattered most to them for Ciro - hope for Ciro’s future! Ciro was accepted into a groundbreaking gene therapy clinical trial at Dayton Children's Hospital. Led by Dr. Lober, pediatric neurosurgeon at Dayton Children’s, this trial offered Ciro and his family a chance to change Ciro’s future. Ciro’s journey is a testament to the exceptional care at Dayton Children’s and the power of hope! For families like the Lavatos, Dayton Children’s isn’t just a hospital – it's a lifeline, a place where the impossible becomes possible, and where every step forward is a victory worth celebrating. ?? For more information about the gene therapy trial, visit clinicaltrials.gov. ?? Read Ciro's story: https://bit.ly/3zKUA6W #DaytonChildrensHospital #DaytonChildrens #AboveAndBeyond4Kids

  • Panacea Venture转发了

    查看Human Longevity, Inc.的公司主页,图片

    25,427 位关注者

    The 2024 Sages& Scientists Symposium concluded with great success last weekend at Harvard University, bringing together thought leaders from diverse fields worldwide to discuss the intersection of medicine and scientific research with the human experience, #holistic wellness, and #spirituality. Among the distinguished speakers were Deepak Chopra MD (official), a renowned expert in mind-body wellness, Sam Altman, a leading figure in artificial intelligence, Abraham Loeb, Chair of Harvard's Department of Astronomy and founder of the Black Hole Project, and Gary Vee, a prominent entrepreneur and business strategist. These influential figures convened to address some of the most urgent global challenges of our time, ranging from mental health and #AI technology to sustainability, the nature of consciousness, and the future of humanity. In key panel discussions titled “Visionary Dialogues,” Dr. Wei-Wu He, Executive Chairman of Human Longevity, Inc. (HLI), and?“Extending Life: The Latest in Longevity and Healthspan Research”with Dr. David Karow, HLI’s President and Chief Innovation Officer, Dr. He and Dr. Karow shared groundbreaking insights into the latest research on extending human life and improving healthspan via technology-enabled clinical longevity practice, a necessarily complement to lifestyle medicine and holistic wellness practices like mindfulness and meditation. The symposium fostered deep interdisciplinary dialogue and sparked innovative thinking, offering fresh perspectives on the advancement of global health and technology, while addressing the critical challenges that lie ahead for humanity's future. Join our newsletter to receive updates on our new and evolving partnership with THE CHOPRA FOUNDATION aiming to bring together the “what” and “why” of longevity for a longer and more fulfilled life: www.humanlongevity.com

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • Panacea Venture转发了

    查看Day Zero Diagnostics, Inc的公司主页,图片

    4,655 位关注者

    Congratulations Alexander Sundermann, DrPH, CIC, FAPIC for a great publication emphasizing the impact genomic surveillance has on the HAI space, both for cost saving and patient health outcomes.

    查看Alexander Sundermann, DrPH, CIC, FAPIC的档案,图片

    Assistant Professor | Outbreaks, Genomic Epidemiology, & Public Health

    Excited to share our latest pre-print on two years of real-time bacterial genomic surveillance for healthcare outbreak detection and mitigation! In this work, we demonstrate that: 1. Weekly bacterial genomic surveillance is not only feasible but impactful. 2. We successfully detected multiple outbreaks early. 3. Directed IP&C interventions. 4. 95% of outbreaks were stopped. 5. We modeled ???? ?????????????????? ????????????????????. ?? 6. All of this led to $??????,?????? ?????? ???????? ??????????????. ?? Our previous retrospective study showed the potential of WGS surveillance for (https://lnkd.in/e-f7QpEu): ? Detecting high-impact outbreaks that often go unnoticed. ? Preventing infections. ? Producing net cost savings. ??????????????, ???????? ?????????? ????????’?? ?????????????????? ???? ????????-????????, ?????? ?????? ???? ?????????????? ????&?? ??????????????????????????. Now, we've shifted to real-time, weekly bacterial genomic surveillance, detecting outbreaks as they occur and alerting IP&C teams. In just two years, we found: ? 3,921 unique infections. ? 476 patients involved in 172 outbreaks. ? Many fascinating outbreak dynamics that we captured early. ? After implementing IP&C interventions, 95.6% of outbreaks stopped along the intervened transmission route. Using a modeling approach & our prior data, we estimated that our interventions ?????????????????? ?????????????????????????? ???? ????????????????????, or 21%—which aligns with prior estimates. The financial impact: The comparison of WGS surveillance costs versus the cost of treating infections resulted in ?????? ?????????????? ???? $??????,?????? ???????? ?????? ??????????. A sensitivity analysis further confirmed that cost savings occurred in 98% of simulations with varying inputs. While there are many important points discussed in the pre-print, ???? ?????????????? ???????? ???????????????? ?????????? ???????????? ???????????????? ???????????????? ?????? ???????????????????? ????????????????????. Current methods often miss outbreaks, while WGS surveillance can not only detect and stop them early but also save money. #healthcare #infectionprevention #genomics Link here or PDF below!: https://lnkd.in/eJpAbgeh

  • Panacea Venture转发了

    查看Inmagene Biopharmaceuticals的公司主页,图片

    1,857 位关注者

    When the world went after oncology, Inmagene was created to go after I&I. When the world was going after ADCC-enhancement in an OX40 mAb, Inmagene was going after ADCC-silencing. When the world is going after OX40L, Inmagene is going after OX40. When the world is escaping from BTK, Inmagene is going after BTK. Inmagene: think different.

    查看Jonathan Wang的档案,图片

    Entrepreneur, scientist, investor

    Inmagene will publish a lot of data about our OX40 (IMG-007) and BTK (IMG-004) compounds at the 2024 European Academy of Dermatology and Venereology (EADV) Congress. IMG-007 is the only clinical stage non-depleting (ADCC silenced) OX40 mAb. It has a half-life longer than all other clinical stage OX40/OX40L compounds we are aware of, enabling the potential for every six months (Q6M) dosing for AD maintenance therapy. https://lnkd.in/gERdZD7n

    Inmagene Announces Three Presentations at the 2024 European Academy of Dermatology and Venereology Congress

    Inmagene Announces Three Presentations at the 2024 European Academy of Dermatology and Venereology Congress

    https://inmagenebio.com

  • Panacea Venture转发了

    查看Domain Therapeutics的公司主页,图片

    8,644 位关注者

    How targeting EP4 receptor can transform #immunotherapy and improve patient outcomes? EP4 antagonists, which inhibit the EP4 receptor, represent a captivating frontier in #immunooncology. A deeper understanding of their potential applications could lead to significant advancements in #cancertreatment. The EP4 receptor is the G protein coupled receptor (GPCR) that, upon binding with its natural Prostaglandin E2 (PGE2), can trigger immune cell modulation, suppressing the immune response and promoting cancer cell survival and proliferation. While COX-2 inhibitors, which aim to inhibit the COX-2 enzyme responsible for PGE2 production, have shown promise in addressing immunosuppression, their development has been hindered by safety concerns. New approaches are needed, and research published in Nature by Jan B?ttcher and George Coukos has linked PGE2 released by tumor cells to the inhibition of tumor-infiltrating lymphocytes (TILs) by modulating IL-2 signaling. Additionally, Julian Downward’s research in AACR Journals highlights that KRAS promotes COX-2 expression leading to PGE2 secretion. Yet, the resistance to KRAS targeting therapies is associated with PGE2 revival, risking tumor relapse. These findings underscore the potential risk of triggering PGE2-mediated immunosuppression in patients undergoing TIL-ACT and KRAS therapies. At Domain, we are unlocking the full therapeutic potential of GPCRs to deliver game-changing therapies. By effectively blocking EP4 receptor, our lead clinical?candidate, DT-9081, has the potential to be best-in-class in dampening immunosuppressive cells while simultaneously boosting the activity of immunocompetent cells, offering an improved safety profile compared to current treatments. With a strong biomarker plan in place, we believe that DT-9081 holds promise in increasing the efficacy of cancer immunotherapies and?extending the range of innovative treatments available to cancer patients. Let’s work together to bring new hope to patients worldwide!????? #CancerResearch #drugdevelopment #biotechnology

  • Panacea Venture转发了

    查看Human Longevity, Inc.的公司主页,图片

    25,427 位关注者

    ?? Join?Human Longevity, Inc.?at the 2024 Sages & Scientists Symposium! ?? This September at Harvard,?Deepak Chopra MD?hosts global leaders for transformative discussions on well-being and humanity’s future. Our Executive Chairman, Dr. Wei-Wu He, and President & Chief of Innovation Officer, Dr. David Karow, will present their groundbreaking research on longevity and HealthSpan. Don’t miss this unique opportunity to engage with visionaries from various fields! ??? Learn More: https://lnkd.in/g-TAzpvg ?? Promo Code: SASBM100 for $100 off! ??? Registration Deadline: September 11, 2024 Be part of a diverse gathering of experts, thinkers, and visionaries! ??? **This event will also be livestreamed at www.sagesandscientists.org during the event dates and times!** #SagesAndScientists?#Longevity?#HealthSpan?#GlobalTransformation?#DeepakChopra?#Innovation?#HumanLongevity?#HarvardEvent?#ChopraFoundation?@THE CHOPRA FOUNDATION?#SagesAndScientists2024?#PeakLiving?@Poonacha Machaiah

    • 该图片无替代文字
  • Panacea Venture转发了

    查看Chime Biologics的公司主页,图片

    873 位关注者

    Chime Biologics strikes gold – twice! ?? ? We're thrilled to announce that Chime Biologics won?two prestigious awards at the Asia-Pacific Biologics CMO Excellence Awards 2024 organized by IMAPAC: ?-Best CDMO Award of the Year ??-Best Biologics CMO Award: Analytical Services ? Mr. James Huang, our Executive Chairman, said, “I am delighted to represent Chime Biologics in receiving these two awards in Singapore. This is not only a recognition of Chime Biologics’ contributions in the field of biopharmaceutical CDMO but also an affirmation of our specialized technical expertise. These achievements are key factors in our ability to gain customer recognition in the biopharmaceutical industry across the Asia Pacific region and globally.” This double triumph is a testament to our commitment to ensuring treatments are both affordable and accessible to everyone, everywhere. From precision analytics to breakthrough biologics, we're setting the standard in service and innovation. Thank you to the brilliant teams, partners, and clients who drive our success. Together, we’re creating the future of biopharma! ?? #CMOExcellence #Biologics #ChimeBiologics #IMAPACAwards #CDMOChampion

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • Panacea Venture转发了

    查看Chime Biologics的公司主页,图片

    873 位关注者

    What a phenomenal discussion on China’s biopharma industry at the BIOHK roundtable! ?? A massive thank you to all those who tuned in and contributed to the conversation on shaping the next decade of healthcare breakthroughs. ? Kudos to the moderator, Peter Pang 彭彼得, our SVP and General Manager of the Shanghai Innovation Center,?for expertly guiding us through the nuances of innovation and strategy! ? And a standing ovation to our stellar panelists: Dr. Tony Wong, CTO, Arbele Dr. Li Ming, CEO,滬港中科國際生物科技有限公司 Dr. Michael Wong, R&D Director,?Immunocure Inc Together, we can chart a course for disruptive discoveries and biotech breakthroughs! ?? ? #Biopharma #Innovation #FutureOfHealth #PharmaLeadership #FutureOfHealth

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
      +1

相似主页